

### CERBIOS APPOINTS FRANCESCA SCARPITTA AS NEW DIRECTOR STRENGTHENING ITS HIGH POTENCY API MANUFACTURING TEAM

Cerbios-Pharma SA (from now on “Cerbios”) is pleased to announce that Dr. Francesca Scarpitta has joined our team as Director of our High Potency Active Ingredients (HPAIs) Production units.

Cerbios is active in the HPAI arena since 1993, when the development of the first HPAI of category 4 (OEL<3ng/m<sup>3</sup>) started. In 2000 we successfully passed the first FDA inspection for an HPAI production with no 483.

This new position was created in order to further strengthen our team in the development and manufacturing of HPAIs, where we have reached a significant exponential growth over the past decade.

As part of our strategy, we have constantly made and will make new investments to expand capacity as well as to keep the highest standard of innovative technology and quality in the industry, with the aim to be a major and recognized player as CDMO for Drug Substances needing high containment where the safety of the operators is essential.



*“Dr. Scarpitta brings in a strong expertise and knowledge in the transfer of API manufacturing from R&D. Scale-up improvements following the development of the HPAI from clinical to commercial scale is one of her key competences”* confirms Dr. Gabriel Haering, CEO

*“Thanks to her contribution we will further boost Cerbios’ vision of excellence in the manufacturing segment of the HPAI contract manufacturing arena which is a fast growing activity with further new investments in the near future”.*

#### **About Francesca Scarpitta.**

Holds a PhD in Organic Chemistry at the University of Pavia. Since 2000 she grew her career in the API industry in Italy and in Israel, having various position in the R&D and in the Operations.

Since over 10 years she has roles of responsibility in the manufacturing of HPAI.

For more details see her profile at this link.

#### **About Cerbios-Pharma SA**

Cerbios is a private company with its headquarters in Lugano, Switzerland, specialized in developing and producing active pharmaceutical ingredients (APIs), both chemical and biological, for its clients around the world. Cerbios is a world leader for some generic products used primarily to treat respiratory, dermatological and oncological diseases.

Cerbios also offers its clients an exclusive service to develop and produce highly active pharmaceutical ingredients (HAPIs) and biological monoclonal antibody tablets, recombinant proteins, conjugated monoclonal antibodies (ADCs) and probiotics for pharmaceutical use.

Cerbios is capable of offering a complete service to develop and register pharmaceutical products, tablets supplied for clinical research phases, the necessary regulatory documentation and subsequent marketing supplies. Cerbios products are marketed around the entire world, primarily in the USA, Japan and Europe.

#### **For more information please contact:**

##### **Cerbios-Pharma SA**

Phone : +41 (0) 91 985 63 11  
Fax : +41 (0) 91 985 63 25  
Email : sales@cerbios.ch

Or use our online [contact form](#).